1
|
Li J, Wang X, Xue L, He Q. Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking. Heliyon 2024; 10:e33103. [PMID: 39022084 PMCID: PMC11253540 DOI: 10.1016/j.heliyon.2024.e33103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 06/09/2024] [Accepted: 06/13/2024] [Indexed: 07/20/2024] Open
Abstract
Objective Curcumin, a phenolic compound extracted from turmeric rhizomes, exhibits antitumour effects in preclinical models of tumours. However, its mechanism of action in prostate cancer remains unclear. Exploring the molecular mechanisms of curcumin in prostate cancer based on network pharmacology and molecular docking provides a new theoretical basis for prostate cancer treatment. Method Using tools such as PharmMapper, SuperPred, TargetNet, and SwissTargetPrediction, we obtained information on curcumin-related targets. We comprehensively collected prostate cancer-related targets from several databases, including GeneCards, CTD, DisGeNET, OMIM, and PharmGKB. Cross-cutting drug-disease targets were then derived by screening using the Venny 2.1.0 tool. Subsequently, we used the DAVID platform to perform in-depth GO and KEGG enrichment analyses of the drug-disease-shared targets. To construct a PPI network map of the cross-targets and screen the 10 core targets, we combined the STRING database and Cytoscape 3.7.2. Molecular docking experiments were performed using AutoDockTools 1.5.7 software. Finally, we used several databases such as GEPIA, HPA, cBioPortal, and TIMER to further analyse the screened core targets in detail. Result We identified 307 key targets of curcumin in cancer treatment. After GO functional enrichment analysis, we obtained 1119 relevant entries, including 782 biological progression (BP) entries, 112 cellular component (CC) entries, and 225 molecular function (MF) entries. In addition, KEGG pathway enrichment analysis revealed 126 signalling pathways, which were mainly involved in the cancer pathway, such as lipid and atherosclerosis pathway, PI3K-Akt signal pathway, MAPK signal pathway, Ras signal pathways, and chemical carcinogenesis-reactive oxygen species. By applying Cytoscape 3.7.2 software, we identified SRC, PIK3R1, STAT3, AKT1, HSP90AA1, ESR1, EGFR, HSP90AB1, MAPK8, and MAPK1 as core targets. Molecular docking experiments showed that the binding energies of curcumin to these core targets were all below -1.85 kJ mol-1, which fully demonstrated that curcumin could spontaneously bind to these core targets. Finally, these results were validated at multiple levels, including mRNA expression, protein expression, and immune infiltration. Conclusion Through in-depth network pharmacology and molecular docking studies, we have found that curcumin may have anticancer potential by upregulating the expression of PIK3R1 and STAT3, and downregulating the binding ability of molecules such as SRC, AKT1, HSP90AA1, ESR1, EGFR, HSP90AB1, MAPK8, and MAPK1. In addition, curcumin may interfere with the cyclic process of prostate cancer cells by inhibiting key signalling pathways such as the PI3K-Akt signalling pathway, MAPK signalling pathway, and Ras, thereby inhibiting their growth. This study not only reveals the potential molecular mechanism of curcumin in the treatment of prostate cancer but also provides an important theoretical basis for subsequent research.
Collapse
Affiliation(s)
- Jun Li
- School of Medicine, Xi'an Jiaotong University, China
- Department of Urology, Ankang Central Hospital, Ankang, 725000, Shaanxi Province, China
| | - Xiong Wang
- Department of Pharmacology, Ankang Maternity and Child Health Care Hospital, Ankang, 725000, Shaanxi Province, China
| | - Li Xue
- Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi Province, China
| | - Qingmin He
- Department of Gastroenterology, Ankang Central Hospital, Ankang, 725000, Shaanxi Province, China
| |
Collapse
|
2
|
Luo D, Wang X, Ramamurthy G, Walker E, Zhang L, Shirke A, Naidu NG, Burda C, Shakya R, Hostnik E, Joseph M, Ponsky L, Ponomarev V, Rosol TJ, Tweedle MF, Basilion JP. Evaluation of a photodynamic therapy agent using a canine prostate cancer model. Prostate 2023; 83:1176-1185. [PMID: 37211857 PMCID: PMC11135201 DOI: 10.1002/pros.24560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/30/2023] [Accepted: 05/04/2023] [Indexed: 05/23/2023]
Abstract
BACKGROUND Male dogs can develop spontaneous prostate cancer, which is similar physiologically to human disease. Recently, Tweedle and coworkers have developed an orthotopic canine prostate model allowing implanted tumors and therapeutic agents to be tested in a more translational large animal model. We used the canine model to evaluate prostate-specific membrane antigen (PSMA)-targeted gold nanoparticles as a theranostic approach for fluorescence (FL) imaging and photodynamic therapy (PDT) of early stage prostate cancer. METHODS Dogs (four in total) were immunosuppressed with a cyclosporine-based immunosuppressant regimen and their prostate glands were injected with Ace-1-hPSMA cells using transabdominal ultrasound (US) guidance. Intraprostatic tumors grew in 4-5 weeks and were monitored by ultrasound (US). When tumors reached an appropriate size, dogs were injected intravenously (iv) with PSMA-targeted nano agents (AuNPs-Pc158) and underwent surgery 24 h later to expose the prostate tumors for FL imaging and PDT. Ex vivo FL imaging and histopathological studies were performed to confirm PDT efficacy. RESULTS All dogs had tumor growth in the prostate gland as revealed by US. Twenty-four hours after injection of PSMA-targeted nano agents (AuNPs-Pc158), the tumors were imaged using a Curadel FL imaging device. While normal prostate tissue had minimal fluorescent signal, the prostate tumors had significantly increased FL. PDT was activated by irradiating specific fluorescent tumor areas with laser light (672 nm). PDT bleached the FL signal, while fluorescent signals from the other unexposed tumor tissues were unaffected. Histological analysis of tumors and adjacent prostate revealed that PDT damaged the irradiated areas to a depth of 1-2 mms with the presence of necrosis, hemorrhage, secondary inflammation, and occasional focal thrombosis. The nonirradiated areas showed no visible damages by PDT. CONCLUSION We have successfully established a PSMA-expressing canine orthotopic prostate tumor model and used the model to evaluate the PSMA-targeted nano agents (AuNPs-Pc158) in the application of FL imaging and PDT. It was demonstrated that the nano agents allowed visualization of the cancer cells and enabled their destruction when they were irradiated with a specific wavelength of light.
Collapse
Affiliation(s)
- Dong Luo
- Department of Radiology, Case Western Reserve University, Cleveland, OH, USA
- Department of Biomedical Science and Engineering, South China University of Technology, Guangzhou, China
| | - Xinning Wang
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | | | - Ethan Walker
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Lifang Zhang
- Department of Radiology, Case Western Reserve University, Cleveland, OH, USA
| | - Aditi Shirke
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Naraen G. Naidu
- Department of Radiology, Case Western Reserve University, Cleveland, OH, USA
| | - Clemens Burda
- Department of Chemistry, Case Western Reserve University, Cleveland, OH, USA
| | - Reena Shakya
- Target Validation Shared Resource, James Comprehensive Cancer Center, The Ohio State University, Columbus Ohio, USA
| | - Eric Hostnik
- College of Veterinary Medicine- Veterinary Medical Center, The Ohio State University, Columbus, OH, USA
| | - Mathew Joseph
- Interventional Cardiology Cath Core Lab, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA
| | - Lee Ponsky
- Department of Urology, University Hospitals, Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA
| | | | - Thomas J. Rosol
- Department of Biomedical Sciences, Ohio University, Athens, OH, USA
| | - Michael F. Tweedle
- Deptartment of Radiology, The Wright Center for Innovation in Biomolecular Imaging, The Ohio State University, Columbus, OH, USA
| | - James P. Basilion
- Department of Radiology, Case Western Reserve University, Cleveland, OH, USA
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
3
|
Thakur N, Quazi S, Naik B, Jha SK, Singh P. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics. Front Oncol 2023; 13:1193736. [PMID: 37664036 PMCID: PMC10469924 DOI: 10.3389/fonc.2023.1193736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Accepted: 07/18/2023] [Indexed: 09/05/2023] Open
Abstract
Prostate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate the growth of prostate cancer cells. Further, PI3K/AKT/mTOR pathways interact with AR signaling pathway and act as precursors to promote prostate cancer. Prostate cancer therapy has been classified into luminal A, luminal B, and basal subtypes. Therapeutic drugs inhibiting dihydrotestosterone and PI3K have shown to give promising results to combat prostate cancer. Many second-generation Androgen receptor signaling antagonists are given either as single agent or with the combination of other drugs. In order to develop a cure for metastasized prostate cancer cells, Androgen deprivation therapy (ADT) is applied by using surgical or chemical methods. In many cases, Prostatectomy or local radiotherapy are used to control metastasized prostate cancer. However, it has been observed that after 1.5 years to 2 years of Prostatectomy or castration, there is reoccurrence of prostate cancer and high incidence of castration resistant prostate cancer is seen in population undergone ADT. It has been observed that Androgen derivation therapy combined with drugs like abiraterone acetate or docetaxel improve overall survival rate in metastatic hormone sensitive prostate cancer (mHSPC) patients. Scientific investigations have revealed that drugs inhibiting poly ADP Ribose polymerase (PARP) are showing promising results in clinical trials in the prostate cancer population with mCRPC and DNA repair abnormalities. Recently, RISUG adv (reversible inhibition of sperm under guidance) has shown significant results against prostate cancer cell lines and MTT assay has validated substantial effects of this drug against PC3 cell lines. Current review paper highlights the advancements in prostate cancer therapeutics and new drug molecules against prostate cancer. It will provide detailed insights on the signaling pathways which need to be targeted to combat metastasized prostate cancer and castration resistant prostate cancer.
Collapse
Affiliation(s)
- Neha Thakur
- Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, India
| | - Sameer Quazi
- Department of Chemistry, Akshara First Grade College, Bengaluru, India
- GenLab Biosolutions Private Limited, Bangalore, Karnataka, India
- Department of Biomedical Sciences, School of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom
- School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
- Solution Chemistry of Advanced Materials and Technologies (SCAMT) Institute, ITMO University, St. Petersburg, Russia
| | - Bindu Naik
- Department of Food Science and Technology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India
| | - Saurabh Kumar Jha
- Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India
- Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali, India
- Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun, India
| | - Pallavi Singh
- Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, India
| |
Collapse
|
4
|
Ballhausen H, Li M, Lombardo E, Landry G, Belka C. Planning CT Identifies Patients at Risk of High Prostate Intrafraction Motion. Cancers (Basel) 2023; 15:4103. [PMID: 37627131 PMCID: PMC10452220 DOI: 10.3390/cancers15164103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 08/11/2023] [Accepted: 08/12/2023] [Indexed: 08/27/2023] Open
Abstract
Prostate motion (standard deviation, range of motion, and diffusion coefficient) was calculated from 4D ultrasound data of 1791 fractions of radiation therapy in N = 100 patients. The inner diameter of the lesser pelvis was obtained from transversal slices through the pubic symphysis in planning CTs. On the lateral and craniocaudal axes, motility increases significantly (t-test, p < 0.005) with the inner diameter of the lesser pelvis. A diameter of >106 mm (ca. 6th decile) is a good predictor for high prostate intrafraction motion (ca. 9th decile). The corresponding area under the receiver operator curve (AUROC) is 80% in the lateral direction, 68% to 80% in the craniocaudal direction, and 62% to 70% in the vertical direction. On the lateral x-axis, the proposed test is 100% sensitive and has a 100% negative predictive value for all three characteristics (standard deviation, range of motion, and diffusion coefficient). On the craniocaudal z-axis, the proposed test is 79% to 100% sensitive and reaches 95% to 100% negative predictive value. On the vertical axis, the proposed test still delivers 98% negative predictive value but is not particularly sensitive. Overall, the proposed predictor is able to help identify patients at risk of high prostate motion based on a single planning CT.
Collapse
Affiliation(s)
- Hendrik Ballhausen
- Department of Radiation Oncology, LMU University Hospital, LMU Munich, 81377 Munich, Germany
| | | | | | | | | |
Collapse
|
5
|
Aydın YM, Şahin AB, Dölek R, Vuruşkan BA, Ocakoğlu G, Vuruşkan H, Yavaşcaoğlu İ, Coşkun B. Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer. Oncol Lett 2023; 25:78. [PMID: 36742361 PMCID: PMC9853097 DOI: 10.3892/ol.2023.13664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 11/29/2022] [Indexed: 01/11/2023] Open
Abstract
Estrogen receptors in prostate cancer (PCa) are a subject of debate. The aim of the present study was to investigate whether estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) impact the biochemical recurrence (BCR) of non-metastatic PCa after surgery. Following the application of the exclusion criteria, data from 108 patients who underwent laparoscopic radical prostatectomy between January 2011 and December 2019 were retrospectively evaluated. A total of 36 patients with BCR constituted the BCR group. The control group was formed using the Propensity Score Matching (PSM) method with a 1:2 ratio, including parameters with well-studied effects on BCR. The median follow-up time was 74.3 (range, 30-127.5) months in the BCR group and 66.6 (range, 31.5-130) months in the control group. Pathology specimens from the two groups were immunohistochemically stained with ERα and ERβ antibodies. Logistic regression analysis and survival analysis were performed. No differences in clinicopathological characteristics were detected between the two groups. The patients with ERα(-)/ERβ(+) staining results had a significantly fewer BCRs than other patients (P=0.024). In the logistic regression analysis, patients with ERα(-)/ERβ(+) PCa also had a significantly lower risk of recurrence (P=0.048). In the survival analysis, the 5-year BCR-free survival rate of patients with ERα(-)/ERβ(+) PCa was higher than that of other patients (85.7 vs. 66.1%; P=0.031). Excluding the effects of well-studied risk factors for recurrence by the PSM method, the present study showed that ERα and ERβ have prognostic value for non-metastatic PCa. The 5-year BCR-free survival rate is significantly higher in patients whose PCa tissue has ERα(-)/ERβ(+) staining results.
Collapse
Affiliation(s)
- Yavuz Mert Aydın
- Department of Urology, Bursa Uludag University, 16059 Bursa, Turkey,Correspondence to: Dr Yavuz Mert Aydın, Department of Urology, Bursa Uludag University, 3 Izmir Street, Gorukle Campus, 16059 Bursa, Turkey, E-mail:
| | | | - Rabia Dölek
- Department of Pathology, Bursa Uludag University, 16059 Bursa, Turkey
| | | | - Gökhan Ocakoğlu
- Department of Biostatistics, Bursa Uludag University, 16059 Bursa, Turkey
| | - Hakan Vuruşkan
- Department of Urology, Bursa Uludag University, 16059 Bursa, Turkey
| | | | - Burhan Coşkun
- Department of Urology, Bursa Uludag University, 16059 Bursa, Turkey
| |
Collapse
|
6
|
Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. Cancers (Basel) 2022; 14:cancers14112717. [PMID: 35681697 PMCID: PMC9179348 DOI: 10.3390/cancers14112717] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 05/24/2022] [Accepted: 05/30/2022] [Indexed: 01/27/2023] Open
Abstract
Simple Summary Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) is an essential imaging tool that is used to locate prostate cancer when it recurs. The results of this scan are used to guide clinical decisions for the management of cancer. However, the long-term effect of these clinical decisions is yet to be determined. In this study, we followed men with recurrent prostate cancer for 3 years after they had a clinical decision made based on a PSMA PET-CT. Our results showed that 75% of men had no addition or change in their treatment plan 3 years after their initial clinical decision was made. In men with a PSMA PET-CT that showed no suspected cancer, 85% had no addition or change to their treatment plan. This indicates that clinical decisions made using PSMA PET-CT in this setting can have a medium- to long-lasting effect. Abstract Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) is a novel imaging modality used to stage recurrent prostate cancer. It has the potential to improve prognostication and ultimately guide the timing of treatment for men with recurrent prostate cancer. This study aims to assess the clinical impact of PSMA PET-CT by analyzing its predictive value of treatment progression after 3 years of follow-up. In this prospective cohort study of 100 men, patients received a PSMA PET-CT for restaging of their disease which was used by a multi-disciplinary team to make a treatment decision. The primary endpoint was treatment progression. This was defined as the addition or change of any treatment modalities such as androgen deprivation therapy (ADT), radiation therapy or chemotherapy. The median follow-up time was 36 months (IQR 24–40 months). No treatment progression was found in 72 (75%) men and therefore 24 (25%) patients were found to have treatment progression. In men with a negative PSMA PET-CT result, 5/33 (15.1%) had treatment progression and 28/33 (84.8%) had no treatment progression. In conclusion, clinical decisions made with PSMA PET-CT results led to 75% of men having no treatment progression at 3 years of follow-up. In men with negative PSMA PET-CT results, this increased to 85% of men.
Collapse
Affiliation(s)
- Sean Ong
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
- Young Urology Researcher’s Organisation, Melbourne, VIC 3000, Australia
- Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia
- Correspondence: ; Tel.: +61-039-426-6666
| | - Claire Pascoe
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
| | - Brian D. Kelly
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia;
- Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia;
| | - Zita Ballok
- Department of Nuclear Medicine, Richmond Medical Imaging, Richmond, VIC 3121, Australia;
| | - David Webb
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
- Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, VIC 3084, Australia
| | - Damien Bolton
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
- Young Urology Researcher’s Organisation, Melbourne, VIC 3000, Australia
- Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia
- Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, VIC 3084, Australia
| | - Declan Murphy
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
- Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia;
| | - Shomik Sengupta
- Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia;
- Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia
| | - Patrick Bowden
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
| | - Nathan Lawrentschuk
- EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia; (C.P.); (D.W.); (D.B.); (D.M.); (P.B.); (N.L.)
- Young Urology Researcher’s Organisation, Melbourne, VIC 3000, Australia
- Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia;
- Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3051, Australia
| |
Collapse
|